Icatibant Ethypharm

Icatibant, the active ingredient in Icatibant Ethypharm, is a bradykinin B2 receptor antagonist presented as a subcutaneous injection for subcutaneous use. It is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in patients with type I or type II disease. GNH USA supplies Icatibant Ethypharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Icatibant acts on the bradykinin pathway to relieve swelling in hereditary angioedema. - Hereditary angioedema type I: rapid reduction of swelling during acute attacks. - Hereditary angioedema type II: rapid reduction of swelling during acute attacks. - Acute HAE attacks in adults: provides prompt symptom relief and shortens attack duration.

Icatibant may cause a range of adverse reactions, most of which are related to the injection site or systemic hypersensitivity.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness: localized erythema around the injection area. - Swelling: transient edema at the site of administration. - Warmth: sensation of heat at the injection site. - Nausea: occasional mild gastrointestinal upset. - Headache: transient mild headache.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Angioedema: unexpected swelling of face, lips, or throat. - Hypotension: sudden drop in blood pressure. - Thrombocytopenia: reduced platelet count observed in rare cases. - Severe injection site reactions: necrosis or ulceration.

Before using Icatibant, consider the following safety measures. - Hypersensitivity: avoid if known allergy to icatibant or any formulation component. - Pregnancy: use only if potential benefit justifies potential risk, as safety data are limited. - Breastfeeding: discontinue nursing or discontinue the drug, based on clinical judgment. - Concomitant ACE inhibitors: monitor closely for enhanced bradykinin effects. - Renal impairment: no dose adjustment required, but monitor clinical response. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant may interact with other medicines that influence the bradykinin system.

Major Interactions (Avoid): - ACE inhibitors: increased bradykinin levels may heighten risk of angioedema. - Angiotensin receptor blockers combined with ACE inhibitors: similar risk of enhanced bradykinin effects.

Moderate Interactions (Monitor Closely): - Estrogen‑containing contraceptives: may affect bradykinin metabolism, requiring observation. - Neprilysin inhibitors: potential additive effect on bradykinin levels. - Other B2 receptor antagonists: may lead to reduced efficacy or unpredictable pharmacodynamics.